Eli Lilly is reducing the price of its weight loss drug, Zepbound, to improve access for patients without insurance coverage. This move follows a deal with the Trump Administration to lower prices for Medicare and Medicaid patients. The drugmaker faces competition from Novo Nordisk’s cheaper alternative, Wegovy, prompting the price cut. Despite concerns, Eli Lilly’s pipeline progress with new weight loss medicines like orforglipron and Retatrutide supports long-term growth. With strong financial results and promising developments, Eli Lilly remains an attractive investment option. Consider the potential for significant returns with other recommended stocks.

Read more at Nasdaq: Eli Lilly’s Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?